Representing RedHill Biopharma in signing a License agreement with Galean Medical Trade

Congratulations to our client RedHill Biopharma (RDHL Nasdaq), on signing a License agreement for Talicia® with Galean Medical Trade for sale and distributing in the United Arab Emirate.
Talicia is a U.S. FDA-approved treatment for a bacterial infection that affects more than 50% of the world’s adult population.
RedHill will receive an upfront payment of $2 million and is eligible for additional milestone payments as well as tiered royalties up to mid-teens on sales of Talicia in the UAE.
Adv. Gershon (Glenn) Shalom-Winter, partner, with specific expertise in private equity transactions, cross-border mergers and acquisitions and technology transfer agreements advised on the agreement.